Re: ZEN-3694 Single Agent Trial Status
in response to
by
posted on
Sep 19, 2017 09:30AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
IMO, I think a deal for both Zenith and RVX has been in the works for over a year and was very close last November but negotiations may have been stalled, maybe a year later with more clinical data from Zenith and where we are with the betonmace trial 4 DSMB safety clearance and a good chance of a positive futility analysis that a deal of any sort could happen at anytime. That being said the only thing we do know is a LOI for a regional license deal from the Aug 28 NR.
My guess is CVR for both companies which DM had mentioned years ago as very good option for both parties ,